Zobrazeno 1 - 10
of 315
pro vyhledávání: '"Andrew L, Feldman"'
Autor:
Kerstin Wenzl, Matthew E. Stokes, Joseph P. Novak, Allison M. Bock, Sana Khan, Melissa A. Hopper, Jordan E. Krull, Abigail R. Dropik, Janek S. Walker, Vivekananda Sarangi, Raphael Mwangi, Maria Ortiz, Nicholas Stong, C. Chris Huang, Matthew J. Maurer, Lisa Rimsza, Brian K. Link, Susan L. Slager, Yan Asmann, Patrizia Mondello, Ryan Morin, Stephen M. Ansell, Thomas M. Habermann, Thomas E. Witzig, Andrew L. Feldman, Rebecca L. King, Grzegorz Nowakowski, James R. Cerhan, Anita K. Gandhi, Anne J. Novak
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract Recent genetic and molecular classification of DLBCL has advanced our knowledge of disease biology, yet were not designed to predict early events and guide anticipatory selection of novel therapies. To address this unmet need, we used an int
Externí odkaz:
https://doaj.org/article/01ad00fd8b6b4753b3568b00e0172eef
Autor:
Luca Arcaini, Côme Bommier, Juan Pablo Alderuccio, Michele Merli, Nicole Fabbri, Maria Elena Nizzoli, Matthew J. Maurer, Vittoria Tarantino, Simone Ferrero, Sara Rattotti, Annalisa Talami, Roberta Murru, Arushi Khurana, Raphael Mwangi, Marina Deodato, Emanuele Cencini, Francesca Re, Carlo Visco, Andrew L. Feldman, Brian K. Link, Marcia Torresan Delamain, Michele Spina, Ombretta Annibali, Alessandro Pulsoni, Andrés J.M. Ferreri, Caterina Cecilia Stelitano, Elsa Pennese, Thomas M. Habermann, Luigi Marcheselli, Sunwoo Han, Isildinha M. Reis, Marco Paulli, Izidore S. Lossos, James R. Cerhan, Stefano Luminari
Publikováno v:
EClinicalMedicine, Vol 72, Iss , Pp 102592- (2024)
Summary: Background: Marginal zone lymphomas (MZL), comprised of three unique but related subtypes, lack a unifying prognostic score applicable to all the patients in need for systemic chemotherapy and/or immunotherapy. Methods: Patients from the pro
Externí odkaz:
https://doaj.org/article/131b6a9da7b1426a967e61af7173f6d4
Autor:
Thomas E. Tavolara, M. Khalid Khan Niazi, Andrew L. Feldman, David L. Jaye, Christopher Flowers, Lee A.D. Cooper, Metin N. Gurcan
Publikováno v:
Diagnostic Pathology, Vol 19, Iss 1, Pp 1-13 (2024)
Abstract Background c-MYC and BCL2 positivity are important prognostic factors for diffuse large B-cell lymphoma. However, manual quantification is subject to significant intra- and inter-observer variability. We developed an automated method for qua
Externí odkaz:
https://doaj.org/article/7c68eb8f1a58429a94ccbcc88f6fa070
Autor:
Cristina Correia, Matthew J. Maurer, Samantha J. McDonough, Paula A. Schneider, Paige E. Ross, Anne J. Novak, Andrew L. Feldman, James R. Cerhan, Susan L. Slager, Thomas E. Witzig, Bruce W. Eckloff, Hu Li, Grzegorz S. Nowakowski, Scott H. Kaufmann
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract How to identify follicular lymphoma (FL) patients with low disease burden but high risk for early progression is unclear. Building on a prior study demonstrating the early transformation of FLs with high variant allele frequency (VAF) BCL2 m
Externí odkaz:
https://doaj.org/article/2262c5bd3f494450bb8803bb96a17ff2
Autor:
Patrizia Mondello, Angelo Fama, Melissa C. Larson, Andrew L. Feldman, Jose C. Villasboas, Zhi-Zhang Yang, Ilia Galkin, Viktor Svelolkin, Ekaterina Postovalova, Alexander Bagaev, Pavel Ovcharov, Arina Varlamova, Sarah Huet, Bruno Tesson, Kaitlyn R. McGrath, Susan Slager, Brian K. Link, Sergei Syrbu, Anne J. Novak, Thomas M. Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski, Gilles Salles, James R. Cerhan, Stephen M. Ansell
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 7, Pp 1-11 (2021)
Abstract Despite a characteristic indolent course, a substantial subset of follicular lymphoma (FL) patients has an early relapse with a poor outcome. Cells in the microenvironment may be a key contributor to treatment failure. We used a discovery an
Externí odkaz:
https://doaj.org/article/0b1f331407cc43f2b978d504ee1e2e66
Autor:
Hyo Jin Kim, Thomas Witzig, Stephen M Ansell, N Nora Bennani, Levi D Pederson, Pamela J Atherton, Ivana N Micallef, Gita Thanarajasingam, Grzegorz S Nowakowski, Andrew L Feldman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 6 (2022)
Externí odkaz:
https://doaj.org/article/75cd9758e6834d9a94a1052256777d1e
Autor:
Joan Enric Ramis-Zaldivar, Blanca Gonzalez-Farre, Alina Nicolae, Svetlana Pack, Guillem Clot, Ferran Nadeu, Anja Mottok, Heike Horn, Joo Y. Song, Kai Fu, George Wright, Randy D. Gascoyne, Wing C. Chan, David W. Scott, Andrew L. Feldman, Alexandra Valera, Anna Enjuanes, Rita M. Braziel, Erlend B. Smeland, Louis M. Staudt, Andreas Rosenwald, Lisa M. Rimsza, German Ott, Elaine S. Jaffe, Itziar Salaverria, Elias Campo
Publikováno v:
Haematologica, Vol 106, Iss 10 (2021)
Plasmablastic lymphoma (PBL) is an aggressive B-cell lymphoma with an immunoblastic/large-cell morphology and terminal B-cell differentiation. The differential diagnosis from Burkitt lymphoma, plasma cell myeloma and some variants of diffuse large B-
Externí odkaz:
https://doaj.org/article/ad4c0e78008445a184ba4c5d1368f5bd
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
The pathogenesis of follicular lymphoma is a multi-step process, in which chromosomal translocation between immunoglobulin heavy chain (IgH) and anti-apoptotic B-cell lymphoma 2 (BCL2), namely IgH-BCL2, is an earliest step, followed by other genetic/
Externí odkaz:
https://doaj.org/article/04874c71b5154931a9da52c9d1ecacca
Autor:
Sanjal H. Desai, Raphael Mwangi, Wern Lynn Ng, Rebecca L. King, Matthew J. Maurer, James R. Cerhan, Andrew L. Feldman, Umar Farooq, Eric Mou, Thomas M. Habermann, Carrie A. Thompson, Yucai Wang, Thomas E. Witzig, Grzegorz S. Nowakowski
Publikováno v:
Blood Advances. 6:6180-6186
An enhanced understanding of the molecular heterogeneity of diffuse large B-cell lymphoma (DLBCL) has opened the door to clinical trials evaluating novel agents with subtype-specific activity. It is an emerging question whether core needle biopsies (
Autor:
Naoki Oishi, Tanya Hundal, Jessica L. Phillips, Surendra Dasari, Guangzhen Hu, David S. Viswanatha, Rong He, Ming Mai, Hailey K. Jacobs, Nada H. Ahmed, Sergei I. Syrbu, Youssef Salama, Jennifer R. Chapman, Francisco Vega, Jagmohan Sidhu, N. Nora Bennani, Alan L. Epstein, L. Jeffrey Medeiros, Mark W. Clemens, Roberto N. Miranda, Andrew L. Feldman
Publikováno v:
Haematologica, Vol 106, Iss 6 (2020)
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a recently characterized T-cell malignancy that has raised significant patient safety concerns and led to worldwide impact on the implants used and clinical management of patients
Externí odkaz:
https://doaj.org/article/b160bd80598140648c1c52e59ac73758